Microheart

Microheart is a Shanghai-based medical technology company specializing in the development of transcatheter solutions for structural heart diseases. The company's core focus is on transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve repair and replacement (TMVR/TMVI) technologies. Its flagship product, the Mi-thos TAVR system, utilizes a self-expanding nitinol frame and bovine pericardium tissue to treat severe aortic stenosis via a minimally invasive approach. Microheart aims to address the significant unmet clinical needs in the cardiovascular space by providing safer and more effective alternatives to traditional open-heart surgery. With a robust pipeline targeting multiple heart valves, the company is positioned as a key player in the rapidly growing Chinese structural heart market.